Sevion Therapeutics Inc  

(Public, OTCMKTS:SVON)   Watch this stock  
Find more results for NYSEAMEX:SNT
-0.019 (-7.78%)
Feb 24 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.23 - 0.27
52 week 0.08 - 0.39
Open 0.26
Vol / Avg. 7,162.00/51,332.00
Mkt cap 4.79M
P/E     -
Div/yield     -
EPS -0.29
Shares 20.74M
Beta 0.64
Inst. own 0%

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin - -11023.91%
Operating margin - -14926.64%
EBITD margin - -4827.52%
Return on average assets -49.43% -57.47%
Return on average equity -99.98% -100.68%
Employees 25 -
CDP Score - -


10210 Campus Point Dr Ste 150
SAN DIEGO, CA 92121-1522
United States - Map
+1-908-8644444 (Phone)
+1-302-6365454 (Fax)

Website links


Sevion Therapeutics, Inc. is a development-stage biotech company. The Company is engaged in building and developing a portfolio of therapeutics, from both internal discovery and acquisition, for the treatment of cancer and immunological diseases. The Company is engaged in the development and licensing of technology to discover and engineer monoclonal antibodies. The Company's product candidates are derived from multiple technology platforms, such as cell-based arrayed antibody discovery, ultralong antibody scaffolds and Chimerasome nanocages. The Company has various antibodies in its preclinical pipeline. The Company's antibody therapeutic candidates target the potassium channel, voltage dependent (Kv1.3) ion channel, which is essential in the pathogenesis of several autoimmune and inflammatory disorders. Other antibodies in its pipeline target cell surface molecules involved in cancer progression.

Officers and directors

David S. Rector Interim President, Interim Chief Executive Officer, Director
Age: 68
James R. Schmidt CPA Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer
Age: 54
James Graziano Ph.D. Chief Technology Officer
Vaughn Smider M.D. Ph.D. Chief Scientific Officer, Director
Miguel de los Rios Ph.D. Vice President - Research
Phillip Frost M.D. Director
Steven Rubin Director
John N. Braca Independent Director